http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010017093-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e67b9307c3b7648c35455e35caa79ecf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c1f83e953ee052a8efe17150dd638c4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D221-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D497-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D515-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
filingDate 2009-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd1cc9d8897d2af67ea2e8b54d368558
publicationDate 2010-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2010017093-A3
titleOfInvention Dopamine receptor ligands with enhanced duration of action
abstract Trans-hexahydrobenzo[a]phenanthridines of the formula (I) wherein X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined herein, are disclosed. Pharmaceutical formulations including such compounds, and methods of using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system are also disclosed.
priorityDate 2008-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006012640-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9324462-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005062894-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228432864
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID681
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18646885
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399686
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457574860
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67331532
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228370027

Total number of triples: 40.